ClinicalTrials.gg
RecruitingNCT07444541Updated Oct 23, 2026

ANO31905 in Combination With Chemotherapy for CLDN18.2-Positive Locally Advanced Unresectable or Metastatic Pancreatic Cancer

A Phase 1/2 interventional study of ANO31905 and AG [gemcitabine+nab-paclitaxel] in Pancreatic Cancer, sponsored by Anova Innovation Limited. Recruiting at 3 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-23.

Sponsored by Anova Innovation Limited · Phase 1/2, Interventional, and Treatment

How we know

Updated Oct 23, 2026Start date movedEligibility revised+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
84
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 1,850 studies in Pancreatic Neoplasms with a site in United States — 297 open to participants now, 469 under way, 25 of them phase 3. Pancreatic Neoplasms · United States.

Planned enrollment
391st of 1,573
84 · median 37
Started
2026
with 82 others
Phase 1/2
222 of 1,850
42 open now
Primary completion
2027-08
later than 235 of 468 live
Registered
1,783rd of 1,850
by date

Among the 1,850 studies in Pancreatic Neoplasms with a site in United States, this one is the 391st largest by planned enrollment of the 1,573 interventional ones that give a count, is one of 83 that started in 2026, is one of 222 in phase 1/2, reaches primary completion later than 235 of the 468 other live ones, and was the 1,783rd registered.

Pancreatic Neoplasms

3,903 studies on the registry are indexed under Pancreatic Neoplasms; 1,005 are open to participants now.

Browse Pancreatic Neoplasms studies →

Open to participants now

297 of the 1,850 studies in Pancreatic Neoplasms with a site in United States are open now. Recruiting first, the newest first:

291 more — sign in →

All 297 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 743 Pancreatic Neoplasms studies recruiting now, 476 (64%) set no upper age limit and 153 (21%) stop at 75 or younger; 40 take children under 18; 60 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,850 studies in Pancreatic Neoplasms with a site in United States, or all of them as a file.
02

Study summary

The goal of this clinical trial is to assess the safety and efficacy of ANO31905 in combination with chemotherapy as the first-line treatment for subjects with CLDN18.2-positive locally advanced unresectable or metastatic pancreatic cancer.

03

Conditions studied

  • Pancreatic Cancer
04

Who can participate

The criteria were revised on the registry on Oct 23, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients voluntarily participate in the study and sign the written ICF;
  2. Males or females aged ≥ 18 at the time of signing the ICF;
  3. (ECOG) performance status score of 0-1;
  4. Expected survival ≥ 3 months;
  5. or cytologically confirmed diagnosis of pancreatic ductal adenocarcinoma (including adenosquamous cell carcinoma) which is locally advanced unresectable or with the first diagnosis within 3 months before the first dose (clinical staging criteria are based on AJCC 8th edition);
  6. Those who have not received any anti-tumor treatment for locally advanced unresectable or metastatic pancreatic ductal adenocarcinoma, including but not limited to surgery, radiotherapy, and chemotherapy; however, if they have received palliative radiotherapy for metastases to bone and/or pain ≥14 days before the first dose of the study treatment and have recovered from all acute toxicities, they can be included. For previous systemic therapy in the and/or adjuvant stage, the time of disease recurrence or progression must be ≥ 6 months after the last dose and within 3 months before the first study dose;
  7. At least one according to v1.1;
  8. Tumor tissue samples are determined to be CLDN18.2-positive by immunohistochemistry (IHC) in the central laboratory, defined as ≥1% of tumor cells with membranous staining intensity ≥1+ determined by IHC;
  9. Patients with sufficient organ function within 7 days before the first study dose;
  10. Non-pregnant or -lactating women; patients of (male and female) must agree to use a reliable method of with their partner from the signing of the ICF until at least 3 months for Cohort A or 6 months for Cohort B (for males) or 6 months for Cohort A or 9 months for Cohort B (for females) after the last dose; female patients of childbearing age must have a negative serum pregnancy test within 7 days before the first study dose.

Exclusion criteria

Exclusion Criteria:

  1. Patients with other malignant tumors except pancreatic adenocarcinoma within 5 years before the first dose of the study treatment (except for in situ cancer of the cervix, basal cell or squamous epithelial cell skin cancer, localized prostate cancer, or ductal carcinoma in situ of the breast);
  2. Patients who have previously received an organ transplant/ bone marrow transplant or are awaiting an organ transplant/allogeneic bone marrow transplant during the expected study period;
  3. Patients who have received treatment with herbal medicines with well documented anti-tumor effects or indications within 14 days before the first study dose;
  4. Patients who have participated in other interventional clinical trials and used interventional measures (such as drugs or devices) within 28 days before the first study dose;
  5. Patients who have undergone major organ surgery (excluding aspiration and venous catheterization) or experienced significant trauma within 28 days before the first study dose;
  6. Patients who have received attenuated within 28 days before the first study dose or are expected to receive attenuated live vaccines during study treatment;
  7. Patients with toxic reactions to previous anti-tumor therapy which haven't recovered to Grade ≤ 1 according to v6.0 criteria (for CRS and ICANS, Grade ≤ 1 as per the ASTCT)),) excluding alopecia (any grade) or other toxic reactions with no safety risk considered by the investigator;
  8. Patients who have previously received treatment targeting CLDN18.2, including but not limited to monoclonal antibodies, bispecific antibodies, chimeric antigen receptor T-cell immunotherapy (CAR-T), or antibody-drug conjugate (ADC);
  9. Patients who have received for systemic use (> 10 mg/day prednisone or equivalent) or other (including but not limited to cyclophosphamide, methotrexate, and thalidomide) within 14 days before the first study dose or expected to receive during study treatment, except that substitution therapy with physiological doses of corticosteroids (ie, ≤ 10 mg/day prednisone or equivalent) is allowed for insufficiency adrenal cortex in the absence of active disorders, topical, ocular, intra-articular, intranasal and inhalation use of glucocorticoids are allowed, and the use of glucocorticoids to prevent contrast media allergy is allowed;
  10. Patients with a history of active autoimmune disorders or autoimmune disorders requiring systemic treatment;
  11. Patients who have previously experienced serious adverse reactions related to immunotherapy, or intolerance to immunotherapy;
  12. Patients with known to any component or of ANO31905, gemcitabine, and nanoparticle albumin-bound paclitaxel;
  13. For Cohort B, use of strong inhibitors or inducers of or use of strong inhibitors of UGT1A1.
  14. For Cohort B, known low or absent dihydropyrimidine dehydrogenase (DPD) activity. Where required by local regulations, testing for DPD deficiency must be performed using a validated method which is recommended by local health authorities.
  15. Patients with known to the central nervous system;
  16. Patients with a poor nutrition condition of indicated by a weight ≤40 kg or (BMI) \<18.0 kg/m2; if symptomatic nutritional support is provided and the condition is corrected before the first study dose, continued screening for enrollment may be considered after assessment by the investigator;
  17. Patients a with serious systemic infection or a medically unexplained fever ≥ 38.5°C (101.3°F) within 28 days before the first study dose;
  18. Patients with severe cardiovascular and cardiovascular diseases;
  19. Presence risks of thrombosis or bleeding:
  20. Patients having severe advanced diseases with comorbidities that may be life-threatening in the short term;
  21. Patients with gastrointestinal diseases that are not suitable for enrollment as judged by the investigator;
  22. Patients with known or suspected interstitial pneumonitis, moderate to severe lung diseases that seriously affect respiratory function
  23. Patients with , , or a known positive history or positive HIV screening;
  24. Patients with other conditions that may place the patients at increased undue study-related risks.
Terms in these criteria, in plain language(22)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
84 participants (estimated)

Study arms

  • Experimental
    ANO31905+AG

    Drug: ANO31905 · Drug: AG [gemcitabine+nab-paclitaxel]

  • Experimental
    ANO31905+mFOLFIRINOX

    Drug: ANO31905 · Drug: mFOLFIRINOX [Oxaliplatin+irinotecan+leucovorin+fluorouracil]

Interventions

  • DrugANO31905

    ANO31905 will be administered as an IV infusion

  • DrugAG [gemcitabine+nab-paclitaxel]

    125 mg/m\^2 of nab-paclitaxel, intravenous infusion, D1/D8/D15 per cycle; 1000 mg/m\^2 of gemcitabine, intravenous infusion, D1/D8/D15 per cycle until PD, intolerable toxicity or other discontinuation criteria specified in the protocol (whichever occurs first).

  • DrugmFOLFIRINOX [Oxaliplatin+irinotecan+leucovorin+fluorouracil]

    Oxaliplatin, 85 mg/m\^2; irinotecan (non-liposome injection), 180 mg/m\^2; leucovorin, 400 mg/m\^2; and fluorouracil, 2400 mg/m\^2 given as a 46-hour continuous infusion, on D1/D15 per cycle.

06

What researchers measure

Primary outcomes

  1. Dose-limiting toxicity (DLT) (Phase Ib).

    The severity of adverse events (AEs) will be graded according to the Common Terminology Criteria for Adverse Events Version 6.0. AEs that occur during the DLT observation period and are judged to be "definitely related", "probably related", or "possibly related" to any investigational products will be deemed as a DLT event.

    Time frame: At the end of Cycle 1 (each cycle is 28 days)

  2. Objective response rate (ORR) assessed by the investigator according to Response Evaluation Criteria for Solid Tumors Version 1.1 (RECIST v1.1) (Phase Ⅱ)

    Objective response rate (ORR) is defined as the proportion of patients with the best efficacy evaluation of complete response (CR) or partial response (PR) during the study. From date of treatment start until disease progression, date of death or withdrawal from study, whichever came first.

    Time frame: Up to 12 months

07

Study locations

3 of 3 sites recruiting
  • Site 01002
    Los Angeles, California 90027, United States
    Recruiting
  • Site 01009
    Plantation, Florida 33322, United States
    Recruiting
  • Site 01005
    San Antonio, Texas 78229, United States
    Recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2026; primary completion for Aug 2027, 8 months later.

Of 114 industry-sponsored phase 1/2 interventional studies under Pancreatic Neoplasms, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 32 and three quarters within 88. This study's planned 8 months is below that.

Counting every sponsor, half of 209 studies reached it within 51 months; a quarter within 36 and three quarters within 89.

Start moved once since we started tracking on Sep 25, 2026: Aug 2026 → Dec 2026, on Oct 23, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Feb 9, 2026
First posted
Mar 3, 2026
StartEst.
Dec 2026was Aug 2026
Primary completionEst.
Aug 2027
CompletionEst.
Dec 2028
Last update
Oct 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
3 sites added, 1 site removed
Show 3 added (3 United States)
  • Site 01002 · Los Angeles, United States
  • Site 01009 · Plantation, United States
  • Site 01005 · San Antonio, United States
Show 1 removed
  • California Research Institute · Los Angeles, United States
Oct 23, 2026
Start date
Aug 2026→Dec 2026
Oct 23, 2026
Eligibility
Criteria largely rewritten (25 changes)
What changed in the criteria
Inclusion criteria
  • AddedPatients voluntarily participate in the study and sign the written ICF;
  • RemovedHistologically or cytologically confirmed diagnosis of pancreatic ductal adenocarcinoma;
  • AddedHistologically or cytologically confirmed diagnosis of pancreatic ductal adenocarcinoma (including adenosquamous cell carcinoma) which is locally advanced unresectable or metastatic with the first diagnosis within 3 months before the first dose (clinical staging criteria are based on AJCC 8th edition);
  • AddedThose who have not received any anti-tumor treatment for locally advanced unresectable or metastatic pancreatic ductal adenocarcinoma, including but not limited to surgery, radiotherapy, and chemotherapy; however, if they have received palliative radiotherapy for metastases to bone and/or pain ≥14 days before the first dose of the study treatment and have recovered from all acute toxicities, they can be included. For previous systemic therapy in the neoadjuvant and/or adjuvant stage, the time of disease recurrence or progression must be ≥ 6 months after the last dose and within 3 months before the first study dose;
  • EditedTumor tissue samples are determined to be CLDN18.2-positive by immunohistochemistry (IHC) in the central laboratory, defined as ≥1% of tumor cells with membranous staining intensity ≥1+ determined by IHC;
  • RemovedNon-pregnant or -lactating women.
  • AddedNon-pregnant or -lactating women; patients of childbearing potential (male and female) must agree to use a reliable method of contraception with their partner from the signing of the ICF until at least 3 months for Cohort A or 6 months for Cohort B (for males) or 6 months for Cohort A or 9 months for Cohort B (for females) after the last dose; female patients of childbearing age must have a negative serum pregnancy test within 7 days before the first study dose.
Exclusion criteria
  • EditedPatients with other malignant tumors except pancreatic adenocarcinoma within 5 years before the first dose of the study treatment; Any previous systematic anti- (except for in situ cancer therapyof the cervix, basal cell or squamous epithelial cell skin cancer, localized prostate cancer, or ductal carcinoma in situ of the breast);
  • RemovedAny previous systematic anti-cancer therapy;
  • RemovedPrevious treatment targeting CLDN18.2;
  • AddedPatients who have previously received an organ transplant/allogeneic bone marrow transplant or are awaiting an organ transplant/allogeneic bone marrow transplant during the expected study period;
  • AddedPatients who have received treatment with herbal medicines with well documented anti-tumor effects or indications within 14 days before the first study dose;
  • AddedPatients who have participated in other interventional clinical trials and used interventional measures (such as drugs or devices) within 28 days before the first study dose;
  • AddedPatients who have undergone major organ surgery (excluding aspiration biopsy and venous catheterization) or experienced significant trauma within 28 days before the first study dose;
  • AddedPatients with toxic reactions to previous anti-tumor therapy which haven't recovered to Grade ≤ 1 according to NCI-CTCAE v6.0 criteria (for CRS and ICANS, Grade ≤ 1 as per the ASTCT)),) excluding alopecia (any grade) or other toxic reactions with no safety risk considered by the investigator;
  • AddedPatients who have previously received treatment targeting CLDN18.2, including but not limited to monoclonal antibodies, bispecific antibodies, chimeric antigen receptor T-cell immunotherapy (CAR-T), or antibody-drug conjugate (ADC);
  • AddedPatients who have received corticosteroids for systemic use (> 10 mg/day prednisone or equivalent) or other immunosuppressants (including but not limited to cyclophosphamide, methotrexate, and thalidomide) within 14 days before the first study dose or expected to receive during study treatment, except that substitution therapy with physiological doses of corticosteroids (ie, ≤ 10 mg/day prednisone or equivalent) is allowed for insufficiency adrenal cortex in the absence of active autoimmune disorders, topical, ocular, intra-articular, intranasal and inhalation use of glucocorticoids are allowed, and the use of glucocorticoids to prevent contrast media allergy is allowed;
  • AddedPatients who have previously experienced serious adverse reactions related to immunotherapy, or intolerance to immunotherapy;
  • AddedFor Cohort B, use of strong inhibitors or inducers of CYP3A or use of strong inhibitors of UGT1A1.
  • AddedFor Cohort B, known low or absent dihydropyrimidine dehydrogenase (DPD) activity. Where required by local regulations, testing for DPD deficiency must be performed using a validated method which is recommended by local health authorities.
  • AddedPatients with a poor nutrition condition of indicated by a weight ≤40 kg or body mass index (BMI) <18.0 kg/m2; if symptomatic nutritional support is provided and the condition is corrected before the first study dose, continued screening for enrollment may be considered after assessment by the investigator;
  • AddedPatients a with serious systemic infection or a medically unexplained fever ≥ 38.5°C (101.3°F) within 28 days before the first study dose;
  • AddedPatients having severe advanced diseases with comorbidities that may be life-threatening in the short term;
  • AddedPatients with known or suspected interstitial pneumonitis, moderate to severe lung diseases that seriously affect respiratory function
  • AddedPatients with hepatitis B, hepatitis C, or a known HIV positive history or positive HIV screening;
Oct 23, 2026
Interventions
Added Drug: ANO31905·Drug: AG [gemcitabine+nab-paclitaxel]·Drug: mFOLFIRINOX [Oxaliplatin+irinotecan+leucovorin+fluorouracil]; removed Biological: ANO31905·Drug: Nanoparticle Albumin-Bound Paclitaxel·Drug: Gemcitabine. Arms added: ANO31905+AG·ANO31905+mFOLFIRINOX; arms removed: ANO31905 (low dose) plus GEM+Nab-P·ANO31905 (high dose) plus GEM+Nab-P
Oct 23, 2026
Contact
Study contact changed: z•••@uthscsa.edu · •••5798→t•••@qilu-pharma.com · •••5798. See the current contact
Oct 23, 2026
Show all 1 update
  1. Oct 23, 2026
    3 sites added, 1 site removed
    Show 3 added (3 United States)
    • Site 01002 · Los Angeles, United States
    • Site 01009 · Plantation, United States
    • Site 01005 · San Antonio, United States
    Show 1 removed
    • California Research Institute · Los Angeles, United States
    Start date Aug 2026→Dec 2026
    Eligibility Criteria largely rewritten (25 changes)
    What changed in the criteria
    Inclusion criteria
    • AddedPatients voluntarily participate in the study and sign the written ICF;
    • RemovedHistologically or cytologically confirmed diagnosis of pancreatic ductal adenocarcinoma;
    • AddedHistologically or cytologically confirmed diagnosis of pancreatic ductal adenocarcinoma (including adenosquamous cell carcinoma) which is locally advanced unresectable or metastatic with the first diagnosis within 3 months before the first dose (clinical staging criteria are based on AJCC 8th edition);
    • AddedThose who have not received any anti-tumor treatment for locally advanced unresectable or metastatic pancreatic ductal adenocarcinoma, including but not limited to surgery, radiotherapy, and chemotherapy; however, if they have received palliative radiotherapy for metastases to bone and/or pain ≥14 days before the first dose of the study treatment and have recovered from all acute toxicities, they can be included. For previous systemic therapy in the neoadjuvant and/or adjuvant stage, the time of disease recurrence or progression must be ≥ 6 months after the last dose and within 3 months before the first study dose;
    • EditedTumor tissue samples are determined to be CLDN18.2-positive by immunohistochemistry (IHC) in the central laboratory, defined as ≥1% of tumor cells with membranous staining intensity ≥1+ determined by IHC;
    • RemovedNon-pregnant or -lactating women.
    • AddedNon-pregnant or -lactating women; patients of childbearing potential (male and female) must agree to use a reliable method of contraception with their partner from the signing of the ICF until at least 3 months for Cohort A or 6 months for Cohort B (for males) or 6 months for Cohort A or 9 months for Cohort B (for females) after the last dose; female patients of childbearing age must have a negative serum pregnancy test within 7 days before the first study dose.
    Exclusion criteria
    • EditedPatients with other malignant tumors except pancreatic adenocarcinoma within 5 years before the first dose of the study treatment; Any previous systematic anti- (except for in situ cancer therapyof the cervix, basal cell or squamous epithelial cell skin cancer, localized prostate cancer, or ductal carcinoma in situ of the breast);
    • RemovedAny previous systematic anti-cancer therapy;
    • RemovedPrevious treatment targeting CLDN18.2;
    • AddedPatients who have previously received an organ transplant/allogeneic bone marrow transplant or are awaiting an organ transplant/allogeneic bone marrow transplant during the expected study period;
    • AddedPatients who have received treatment with herbal medicines with well documented anti-tumor effects or indications within 14 days before the first study dose;
    • AddedPatients who have participated in other interventional clinical trials and used interventional measures (such as drugs or devices) within 28 days before the first study dose;
    • AddedPatients who have undergone major organ surgery (excluding aspiration biopsy and venous catheterization) or experienced significant trauma within 28 days before the first study dose;
    • AddedPatients with toxic reactions to previous anti-tumor therapy which haven't recovered to Grade ≤ 1 according to NCI-CTCAE v6.0 criteria (for CRS and ICANS, Grade ≤ 1 as per the ASTCT)),) excluding alopecia (any grade) or other toxic reactions with no safety risk considered by the investigator;
    • AddedPatients who have previously received treatment targeting CLDN18.2, including but not limited to monoclonal antibodies, bispecific antibodies, chimeric antigen receptor T-cell immunotherapy (CAR-T), or antibody-drug conjugate (ADC);
    • AddedPatients who have received corticosteroids for systemic use (> 10 mg/day prednisone or equivalent) or other immunosuppressants (including but not limited to cyclophosphamide, methotrexate, and thalidomide) within 14 days before the first study dose or expected to receive during study treatment, except that substitution therapy with physiological doses of corticosteroids (ie, ≤ 10 mg/day prednisone or equivalent) is allowed for insufficiency adrenal cortex in the absence of active autoimmune disorders, topical, ocular, intra-articular, intranasal and inhalation use of glucocorticoids are allowed, and the use of glucocorticoids to prevent contrast media allergy is allowed;
    • AddedPatients who have previously experienced serious adverse reactions related to immunotherapy, or intolerance to immunotherapy;
    • AddedFor Cohort B, use of strong inhibitors or inducers of CYP3A or use of strong inhibitors of UGT1A1.
    • AddedFor Cohort B, known low or absent dihydropyrimidine dehydrogenase (DPD) activity. Where required by local regulations, testing for DPD deficiency must be performed using a validated method which is recommended by local health authorities.
    • AddedPatients with a poor nutrition condition of indicated by a weight ≤40 kg or body mass index (BMI) <18.0 kg/m2; if symptomatic nutritional support is provided and the condition is corrected before the first study dose, continued screening for enrollment may be considered after assessment by the investigator;
    • AddedPatients a with serious systemic infection or a medically unexplained fever ≥ 38.5°C (101.3°F) within 28 days before the first study dose;
    • AddedPatients having severe advanced diseases with comorbidities that may be life-threatening in the short term;
    • AddedPatients with known or suspected interstitial pneumonitis, moderate to severe lung diseases that seriously affect respiratory function
    • AddedPatients with hepatitis B, hepatitis C, or a known HIV positive history or positive HIV screening;
    Interventions Added Drug: ANO31905·Drug: AG [gemcitabine+nab-paclitaxel]·Drug: mFOLFIRINOX [Oxaliplatin+irinotecan+leucovorin+fluorouracil]; removed Biological: ANO31905·Drug: Nanoparticle Albumin-Bound Paclitaxel·Drug: Gemcitabine. Arms added: ANO31905+AG·ANO31905+mFOLFIRINOX; arms removed: ANO31905 (low dose) plus GEM+Nab-P·ANO31905 (high dose) plus GEM+Nab-P
    Contact Study contact changed: z•••@uthscsa.edu · •••5798→t•••@qilu-pharma.com · •••5798. See the current contact
    + 3 other changes: index terms, verification date and design details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07444541
Lead sponsor
Anova Innovation Limited
Responsible party
Sponsor
First posted
Mar 3, 2026
Start date
Dec 2026 (estimated)
Primary completion
Aug 2027 (estimated)
Completion
Dec 2028 (estimated)
Last update
Oct 23, 2026

Study contacts

Tiana Zhao
Contact
tiana.zhao@qilu-pharma.com
210-450-5798

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion